NCT05409924View on ClinicalTrials.gov

First-in-human Single and Multiple Dose Trial of ATR-258

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

October 4, 2023

Study Completion Date

October 4, 2023

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

ATR-258

Single Ascending Dose

DRUG

ATR-258

Multiple Ascending Dose

DRUG

ATR-258

Repeat Dose

Trial Locations (1)

Unknown

CRS Clinical Research Services, Mannheim

Sponsors

Lead Sponsor

Atrogi AB
All Listed Sponsors
collaborator

Key2Compliance

INDUSTRY

collaborator

CRS Clinical Research Services Mannheim GmbH

INDUSTRY

lead

Atrogi AB

INDUSTRY